Search
Metagenomi Inc
MGXAdd to Watchlist
1.260USD
+0.050+4.13%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
47.44MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+4.13%
5 Days
+0.80%
1 Month
-5.26%
6 Months
-24.55%
Year to Date
-22.22%
1 Year
-24.55%
Key Figures
1.220Open
1.270High
355.93KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.95%Turnover Ratio
1.210Prev. Close
1.170Low
340.60KTurnover
LossP/E Static
0.34P/B
0.00%Div Yield TTM
-34.71%ROA
3.95052wk High
2.80Volume Ratio
-78.06MNet Profit
37.65MShares
-2.2960EPS TTM
--Beta
-49.02%ROE
1.23052wk Low
8.26%Amplitude
100.00%Gross Margin
47.44MMarket Cap
-2.16Reward/Risk
4.18%Risk Rate
TradingKey Stock Score of Metagenomi Inc
Currency: USD Updated: 2026-07-02Key Insights
Metagenomi Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 180 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.33.In the medium term, the stock price is expected to remain stable.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Metagenomi Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Metagenomi Inc Highlights
StrengthsRisks
Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
Growing
The company is in a growing phase, with the latest annual income totaling USD 25.21M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 25.21M.
Overvalued
The company’s latest PE is -0.55, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 8.82M shares, decreasing 42.09% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 11.64K shares of this stock.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
8.333
Target Price
+588.70%
Upside Space
Metagenomi Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Metagenomi Inc Info
Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
Ticker SymbolMGX
CompanyMetagenomi Inc
CEOIrish (Jian)
Websitehttps://metagenomi.co/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Metagenomi Inc (MGX)?
The current price of Metagenomi Inc (MGX) is 1.26.
What is the symbol of Metagenomi Inc?
The ticker symbol of Metagenomi Inc is MGX.
What is the 52-week high of Metagenomi Inc?
The 52-week high of Metagenomi Inc is 3.95.
What is the 52-week low of Metagenomi Inc?
The 52-week low of Metagenomi Inc is 1.23.
What is the market capitalization of Metagenomi Inc?
The market capitalization of Metagenomi Inc is 47.44M.
Is Metagenomi Inc (MGX) currently rated as Buy, Hold, or Sell?
According to analysts, Metagenomi Inc (MGX) has an overall rating of Buy, with a price target of 8.33.
What is the Earnings Per Share (EPS TTM) of Metagenomi Inc (MGX)?
The Earnings Per Share (EPS TTM) of Metagenomi Inc (MGX) is -2.36.